Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.
- DOI
- 10.1111/dom.71314
- Published
- 2026 Sep 9
- Container
- Diabetes, obesity & metabolism
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.71314,
title = {Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.},
author = {Sakai T and Ishibashi R and Koshizaka M and Takatsuna Y and Tatsumi T and Baba T and Sakurai K and Maezawa Y and Yokote K},
year = {2026},
journal = {Diabetes, obesity \& metabolism},
doi = {10.1111/dom.71314},
url = {https://doi.org/10.1111/dom.71314}
}RIS
TY - JOUR TI - Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial. AU - Sakai T AU - Ishibashi R AU - Koshizaka M AU - Takatsuna Y AU - Tatsumi T AU - Baba T AU - Sakurai K AU - Maezawa Y AU - Yokote K PY - 2026 JO - Diabetes, obesity & metabolism DO - 10.1111/dom.71314 UR - https://doi.org/10.1111/dom.71314 ER -
APA
T, S., R, I., M, K., Y, T., T, T., T, B., K, S., Y, M., & K, Y. (2026). Renal Safety of Intravitreal Ranibizumab and the Effects of SGLT2 Inhibition in Diabetic Macular Oedema: A Post Hoc Analysis of the COMET Trial.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.71314
Source records
- pubmed · retrieved 2026-09-25T22:20:47.201Z